Jeyran Shahbazi

Sydney, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial.

96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial.

Journal: The International journal on drug policy

Published: September 25, 2023

Tinkering with care: Implementing extended-release buprenorphine depot treatment for opioid dependence.

Tinkering with care: Implementing extended-release buprenorphine depot treatment for opioid dependence.

Journal: The International journal on drug policy

Published: August 16, 2023

Provider costs of treating opioid dependence with extended-release buprenorphine in Australia.

Provider costs of treating opioid dependence with extended-release buprenorphine in Australia.

Journal: Drug and alcohol review

Published: August 06, 2023

Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot.

Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot.

Journal: The International journal on drug policy

Published: March 03, 2022

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.

Journal: The International journal on drug policy

Published: August 02, 2021

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study.

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study.

Journal: BMJ open

Published: August 02, 2020

The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.

The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 17, 2015

Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1.

Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1.

Journal: Oncotarget

Published: June 23, 2014

Tumor Protein 53-Induced Nuclear Protein 1 Enhances p53 Function and Represses Tumorigenesis.

Tumor Protein 53-Induced Nuclear Protein 1 Enhances p53 Function and Represses Tumorigenesis.

Journal: Frontiers in genetics

Published: January 29, 2013

Showing 1-9 of 9

Last Updated: 09/26/2026